Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Used in scans for recurrent or metastatic breast cancer. Sold as Cerianna. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Fluoroestradiol F-18 (sold as Cerianna), first approved May 20, 2020, with 0 new uses approved and 0 published complete response letters.
Application: 1
New uses approved: 0
Complete response letters: 0
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
Cases
11
Serious
1 (9%)
Deaths reported
0
By quarter
2025 Q4: 2 · 2026 Q1: 3 · 2026 Q2: 3 · 2026 Q3: 3
Most reported reactions
No adverse event (6), Seizure (2), Drug ineffective (2), Radioisotope scan abnormal (2), Radiation necrosis (1), Mental status changes (1), Metastases to meninges (1), Gait disturbance (1), Lethargy (1), Staphylococcal bacteraemia (1)
Clinical trials
5 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA